Literature DB >> 24395613

Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD.

Reena Khanna1, Brian G Feagan.   

Abstract

OPINION STATEMENT: Although tumor necrosis factor (TNF)-antagonists are highly effective agents for the treatment of inflammatory bowel diseases (IBD), up to 40 % of patients ultimately lose response. As a result of the limited availability of treatment options, empiric dose escalation or switching of TNF-antagonists have evolved as strategies to regain response. Recently, therapeutic drug monitoring (TDM) (measurement of serum drug and antidrug antibody concentrations) has emerged to facilitate informed decision-making in patients with secondary loss of response to a TNF-antagonist. The evidence supporting the use of TDM in clinical practice and future applications of this approach will be discussed.

Entities:  

Year:  2014        PMID： 24395613     DOI： 10.1007/s11938-013-0005-4

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN： 1092-8472


  59 in total

1.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

Authors:  Richard J Farrell; Mazen Alsahli; Yoon-Tae Jeen; Kenneth R Falchuk; Mark A Peppercorn; Pierre Michetti
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

Review 2.  Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease.

Authors:  M Chaparro; I Guerra; P Muñoz-Linares; J P Gisbert
Journal:  Aliment Pharmacol Ther       Date:  2012-03-22       Impact factor: 8.171

3.  A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms• Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between ATA and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients• Serum Adalimumab Levels and Antibodies Correlate with Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients with Inflammatory Bowel Disease• Comparison of Early Measurement of Infliximab and Antibodies-to-Infliximab Serum Levels with Standard Trough Analysis• Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday• A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab• Preoperative Serum Biologic Levels Do Not Impact Postoperative Outcomes in Ulcerative Colitis• Higher Preoperative Serum Biologic Levels Are Associated with Postoperative Complications in Crohn's Disease PatientsWith Expert Commentary by: William J. Sandborn, MDProfessor and Chief, Division of GastroenterologyDirector, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-08

4.  Abatacept for Crohn's disease and ulcerative colitis.

Authors:  William J Sandborn; Jean-Frederic Colombel; Bruce E Sands; Paul Rutgeerts; Stephan R Targan; Remo Panaccione; Brian Bressler; Karl Geboes; Stefan Schreiber; Richard Aranda; Sheila Gujrathi; Allison Luo; Yun Peng; Luisa Salter-Cid; Stephen B Hanauer
Journal:  Gastroenterology       Date:  2012-04-12       Impact factor: 22.682

5.  Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease.

Authors:  Benjamin Pariente; Guillaume Pineton de Chambrun; Roman Krzysiek; Marine Desroches; Gauthier Louis; Chiara De Cassan; Clotilde Baudry; Jean-Marc Gornet; Pierre Desreumaux; Dominique Emilie; Jean-Frédéric Colombel; Matthieu Allez
Journal:  Inflamm Bowel Dis       Date:  2011-08-29       Impact factor: 5.325

6.  Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.

Authors:  Casper Steenholdt; Klaus Bendtzen; Jørn Brynskov; Ole Ø Thomsen; Mark A Ainsworth
Journal:  Am J Gastroenterol       Date:  2014-05-06       Impact factor: 10.864

7.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 8.  Therapeutic drug monitoring of biologics for inflammatory bowel disease.

Authors:  Jean-Frédéric Colombel; Brian G Feagan; William J Sandborn; Gert Van Assche; Anne M Robinson
Journal:  Inflamm Bowel Dis       Date:  2011-10-21       Impact factor: 5.325

9.  Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.

Authors:  Y Mazor; R Almog; U Kopylov; D Ben Hur; A Blatt; A Dahan; M Waterman; S Ben-Horin; Y Chowers
Journal:  Aliment Pharmacol Ther       Date:  2014-07-15       Impact factor: 8.171

Review 10.  Serum level monitoring of antibacterial drugs. A review.

Authors:  M Wenk; S Vozeh; F Follath
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447
View more
  1 in total

Review 1.  Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab.

Authors:  Jill Mv Petkau; Bertus Eksteen
Journal:  Biologics       Date:  2016-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.